Reflux Esophagitis
Conditions
Interventions
esomeprazole 20mg/day for 8 weeks p.o.
Sponsors
Nagoya University Graduate School of Medicine, Department of Gastroentelorogy and Hepatology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patient who is diagnosed as a reflux esophagitis and has been treated with PPI (expect for esomaprazole) for 4weeks, but GerdQ questionare shows insufficient therapeutic effect.
Exclusion criteria
Exclusion criteria: 1,Patients with a history of hypersensitivity to the study drug. 2,Patients in the administration of atazanavir sulfate or a Rirupibirin hydrochloride. 3,Patients with confirmed gastric ulcer, duodenal ulcer by endoscopy. 4,Patients who have unstable merger liver, kidney, heart disease or serious medical conditions. 5,History of gastrointestinal tract resection or vagotomy. 6,Pregnancy and lactation. 7,Patients treated with esomeprazole 14 days before obtaining informed consent 8,Patient in need of administration of the following agents other than the study drug during the study period (Excluding test drug), histamine H2-receptor antagonist, prokinetics, gastric mucosal protection, anticholinergic drugs, antacids, antidepressants, anti-anxiety drugs, steroids, bisphosphonates. 9,Patients who judged unsuitable for research participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate by GerdQ questionnaire 4, 8 weeks after administration of esomeprazole | — |
Secondary
| Measure | Time frame |
|---|---|
| Influence of CYP2C19 Polymorphism on esomaplazole responsiveness | — |
Countries
Japan
Contacts
Public ContactKohei Funasaka
Nagoya University Graduate School of Medicine Department of Gastroenterology and Hepatology
Outcome results
None listed